CVE:KNE - Kane Biotech Stock Price, News & Analysis

0.00 (0.00 %)
(As of 09/18/2019 04:00 PM ET)
Today's Range
Now: C$0.14
50-Day Range
MA: C$0.14
52-Week Range
Now: C$0.14
Volume77,700 shs
Average Volume63,269 shs
Market CapitalizationC$11.22 million
P/E RatioN/A
Dividend YieldN/A
Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesC$1.13 million
Cash FlowC$0.02 per share
Book ValueC$0.00 per share



Market CapC$11.22 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive KNE News and Ratings via Email

Sign-up to receive the latest news and ratings for KNE and its competitors with MarketBeat's FREE daily newsletter.

Kane Biotech (CVE:KNE) Frequently Asked Questions

What is Kane Biotech's stock symbol?

Kane Biotech trades on the Canadian Venture Exchange (CVE) under the ticker symbol "KNE."

When is Kane Biotech's next earnings date?

Kane Biotech is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Kane Biotech.

Has Kane Biotech been receiving favorable news coverage?

Media coverage about KNE stock has been trending negative on Wednesday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kane Biotech earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Kane Biotech.

Who are some of Kane Biotech's key competitors?

Who are Kane Biotech's key executives?

Kane Biotech's management team includes the folowing people:
  • Mr. Marc Edwards, Interim CEO & Director
  • Mr. Ray Dupuis, Chief Financial Officer
  • Mr. Mark Ahrens-Townsend, Advisor
  • Dr. Gordon Guay, Chief Scientific Officer & Member of Scientific Advisory Board
  • Mr. L. Michael Coutts, Director of Bus. Devel.

How do I buy shares of Kane Biotech?

Shares of KNE and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Kane Biotech's stock price today?

One share of KNE stock can currently be purchased for approximately C$0.14.

How big of a company is Kane Biotech?

Kane Biotech has a market capitalization of C$11.22 million and generates C$1.13 million in revenue each year. View Additional Information About Kane Biotech.

What is Kane Biotech's official website?

The official website for Kane Biotech is

How can I contact Kane Biotech?

Kane Biotech's mailing address is 162-196 Innovation Dr, WINNIPEG, MB R3T 6C5, Canada. The company can be reached via phone at +1-204-4531301.

MarketBeat Community Rating for Kane Biotech (CVE KNE)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  108
MarketBeat's community ratings are surveys of what our community members think about Kane Biotech and other stocks. Vote "Outperform" if you believe KNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/18/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel